Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer

Rajitha, Balney; Belalcazar, Astrid; Nagaraju, Ganji Purnachandra; Shaib, Walid Labib; Snyder, James P.; Miyake, Shoji; Pattnaik, Subasini; Alam, Afroz; El‐Rayes, Bassel F.

doi:10.1016/j.canlet.2016.01.052

Cited by 73 publications

(42 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anitha et al also showed curcumin‐loaded thiolated chitosan nanoparticles (CRC‐TCS‐NPs) can induce G2/M arrest in HT‐29 colon cancer cells . Rajitha et al indicated curcumin analogs can induce G0/G1 arrest in two CRC cell lines (HCT116 and HT29) . Our flow cytometry measurements by annexin V/PI staining also showed apoptosis in dose dependent manner in the CPNs‐treated cells after 24 hours, and DAPI staining confirmed that HT29 treated cells seemed to show some nuclear morphological changes with increasing the time of incubation at the dose of 14 μg/ml (IC50).…”

Section: Discussionsupporting

confidence: 68%

Polymersome‐assisted delivery of curcumin: A suitable approach to decrease cancer stemness markers and regulate miRNAs expression in HT29 colorectal cancer cells

Pakizehkar

Ranji

Sohi

et al. 2019

Polymers for Advanced Techs

View full text Add to dashboard Cite

Curcumin as a safe traditional compound has various benefits such as anticancer activities. However, low solubility in water is a problem. Herein, curcumin encapsulated in polymersome nanoparticles (CPNs) have been developed, the physicochemical properties have been evaluated, and cytotoxicity effects on HT29 cells were evaluated by MTT assay and annexin V/PI staining. The expression of stemness markers including CD44, CD133, and CD24, as well as miRNAs (miR‐126, miR‐34a, miR‐21, miR‐155, miR‐221, and miR‐222) and some potential targets, was evaluated in CPNs‐treated and untreated cells. Physicochemical analysis confirmed the encapsulation of curcumin in polymersomes and showed a spherical shape, an appropriate mean size of 259.5±1.5 nm, the acceptable polydispersity index of ~ 0.465, and the zeta potential of (‐8.74±0.2), as well as long‐term storage of CPNs at 4°C. According to the result, CPNs with the IC50 of 14 μg/ml increased apoptosis and induced S arrest in treated cells. Flow cytometry analysis showed the decrease in cancer stemness markers. RT‐qPCR analysis identified the downregulation of miR‐21, miR‐155, and miR‐221/222, as well as upregulation of miR‐34a, miR‐126, and deregulation of some apoptotic targets such as P53, CASP9, CASP8, CASP3, BAX, and BCl‐2 in CPNs‐treated cells. As a result, CPNs can be a safe and effective complementary agent to diminish cancer stem cells and tumor recurrence in colorectal cancer therapy.

show abstract

Section: Discussionsupporting

confidence: 68%

Polymersome‐assisted delivery of curcumin: A suitable approach to decrease cancer stemness markers and regulate miRNAs expression in HT29 colorectal cancer cells

Pakizehkar

Ranji

Sohi

et al. 2019

Polymers for Advanced Techs

View full text Add to dashboard Cite

show abstract

“…Several research groups have suggested that curcumin induces cell death in cancer and leukemia chemotherapy-resistant cells; however, the mechanisms by which curcumin induces cell death appear to be different and dose-dependent in various cell types [27]. Curcumin is considered as a potent inducer of apoptosis in cancer cells, mainly by arresting cells in G1 or G2 phase [28–30], but the underlying mechanisms are still unclear. Therefore, a more detailed analysis of the effect of curcumin in cancer and leukemia cells is required for a better understanding of its anti-oncogenic potential.…”

Section: Discussionmentioning

confidence: 99%

A Subpopulation of the K562 Cells Are Killed by Curcumin Treatment after G2/M Arrest and Mitotic Catastrophe

et al. 2016

View full text Add to dashboard Cite

Curcumin is extensively investigated as a good chemo-preventive agent in the development of many cancers and particularly in leukemia, including treatment of chronic myelogenous leukemia and it has been proposed as an adjuvant for leukemia therapies. Human chronic myeloid leukemia cells (K562), were treated with 20 μM of curcumin, and we found that a subpopulation of these cells were arrested and accumulate in the G2/M phase of the cell cycle. Characterization of this cell subpopulation showed that the arrested cells presented nuclear morphology changes resembling those described for mitotic catastrophe. Mitotic cells displayed abnormal chromatin organization, collapse of the mitotic spindle and abnormal chromosome segregation. Then, these cells died in an apoptosis dependent manner and showed diminution in the protein levels of BCL-2 and XIAP. Moreover, our results shown that a transient activation of the nuclear factor κB (NFκB) occurred early in these cells, but decreased after 6 h of the treatment, explaining in part the diminution of the anti-apoptotic proteins. Additionally, P73 was translocated to the cell nuclei, because the expression of the C/EBPα, a cognate repressor of the P73 gene, was decreased, suggesting that apoptosis is trigger by elevation of P73 protein levels acting in concert with the diminution of the two anti-apoptotic molecules. In summary, curcumin treatment might produce a P73-dependent apoptotic cell death in chronic myelogenous leukemia cells (K562), which was triggered by mitotic catastrophe, due to sustained BAX and survivin expression and impairment of the anti-apoptotic proteins BCL-2 and XIAP.

show abstract

“…NF-κB plays a very important role in establishing the relation between inflammation and cancer. 14,48 Moreover, CUR is safe and well tolerated even at very high doses. Cheng et al 49 studied safety of CUR in humans and showed that CUR when taken at 8 g daily for 3 months did not produce any toxic effect.…”

Section: 45mentioning

confidence: 99%

Liposomal curcumin and its application in cancer

Feng¹,

Wei²,

Lee³

et al. 2017

IJN

316

208

View full text Add to dashboard Cite

Curcumin (CUR) is a yellow polyphenolic compound derived from the plant turmeric. It is widely used to treat many types of diseases, including cancers such as those of lung, cervices, prostate, breast, bone and liver. However, its effectiveness has been limited due to poor aqueous solubility, low bioavailability and rapid metabolism and systemic elimination. To solve these problems, researchers have tried to explore novel drug delivery systems such as liposomes, solid dispersion, microemulsion, micelles, nanogels and dendrimers. Among these, liposomes have been the most extensively studied. Liposomal CUR formulation has greater growth inhibitory and pro-apoptotic effects on cancer cells. This review mainly focuses on the preparation of liposomes containing CUR and its use in cancer therapy.

show abstract

Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer

Cited by 73 publications

References 29 publications

Polymersome‐assisted delivery of curcumin: A suitable approach to decrease cancer stemness markers and regulate miRNAs expression in HT29 colorectal cancer cells

Polymersome‐assisted delivery of curcumin: A suitable approach to decrease cancer stemness markers and regulate miRNAs expression in HT29 colorectal cancer cells

A Subpopulation of the K562 Cells Are Killed by Curcumin Treatment after G2/M Arrest and Mitotic Catastrophe

Liposomal curcumin and its application in cancer

Contact Info

Product

Resources

About